TABLE 1.
Baseline characteristics
| Variable | Overall | PWIDs | MSM | Other |
|---|---|---|---|---|
| Patients (n [%]) | 1870 (100) | 306 (16.4) | 891 (47.6) | 673 (36.0) |
| Sex (n [%]) | ||||
| Male | 1437 (76.8) | 196 (64.1) | 891 (100) | 350 (52.0) |
| Female | 433 (23.2) | 110 (35.9) | 0 (0.0) | 323 (48.0) |
| Age (years) at BL [median (IQR)] | 36.5 (14.8) | 32.1 (12.7) | 37.4 (14.1) | 37.3 (15.9) |
| Advanced Fibrosis at BL (n [%]) according to | ||||
| Transient elastography >9.5kPa | 41 (2.2) | 25 (8.2) | 11 (1.2) | 5 (0.7) |
| Missing values | 1736 (92.8) | 210 (68.6) | 855 (95.6) | 671 (99.7) |
| FIB‐4 score >3.25 a | 72 (3.9) | 22 (7.2) | 23 (2.6) | 27 (4.0) |
| No fibrosis evaluation | 255 (13.6) | 31 (10.1) | 137 (15.4) | 87 (12.9) |
| HCV‐RNA >12 IU/mL at BL (n [%]) | 197 (10.5) | 155 (50.7) | 18 (2.0) | 24 (3.6) |
| Protective anti‐HBs at BL (n [%]) | 793 (42.4) | 108 (35.3) | 464 (52.1) | 221 (32.8) |
| HBsAg(+) at BL (n [%]) | 79 (4.2) | 22 (7.2) | 36 (4.0) | 21 (3.1) |
| HBV‐DNA at BL | ||||
| >12 IU/mL (n [%]) | 38 (2.0) | 11 (3.6) | 16 (1.8) | 11 (1.6) |
| ART (n [%]) | ||||
| No ART at BL, but later | 1799 (96.2) | 296 (96.7) | 849 (95.3) | 653 (97.0) |
| No ART at BL, never ART during FU | 60 (3.2) | 8 (2.6) | 33 (3.7) | 19 (2.8) |
| ART at baseline | 11 (0.6) | 2 (0.7) | 8 (0.9) | 1 (0.1) |
| HIV‐RNA at BL | ||||
| Viral load (log10/mL) [median (IQR)] | 4.6 (1.8) | 4.6 (1.7) | 4.7 (1.8) | 4.6 (1.8) |
| HIV‐RNA suppression (<1.7 log10/mL) (n [%]) | 289 (15.5) | 37 (12.1) | 145 (16.3) | 107 (15.9) |
| Missing values (n [%]) | 49 (2.6) | 4 (1.3) | 34 (3.8) | 11 (1.6) |
| CD4 count at BL (cells/µL) (median [IQR]) | 357 (339.0) | 399 (414.0) | 361 (344.0) | 336 (318.0) |
| Unknown (n [%]) | 40 (2.1) | 2 (0.7) | 27 (3.0) | 11 (1.6) |
| CDC stage at BL (n [%]) | ||||
| A1‐A3 | 1479 (79.1) | 235 (76.8) | 711 (79.8) | 533 (79.2) |
| B1‐B3 | 92 (4.9) | 15 (4.9) | 44 (4.9) | 33 (4.9) |
| C1‐C3 | 139 (7.4) | 26 (8.5) | 57 (6.4) | 56 (8.3) |
| AIDS | 433 (23.2) | 82 (26.8) | 179 (20.0) | 172 (25.6) |
| Unknown | 160 (8.6) | 30 (9.8) | 79 (8.9) | 51 (7.6) |
Abbreviations: AIDS, acquired immune deficiency syndrome; anti‐HBs, anti‐hepatitis B surface antibodies; ART, antiretroviral therapy; BL, baseline; CDC, Centers for Disease Control and Prevention; DNA, deoxyribonucleic acid; FIB‐4, fibrosis‐4 score; FU, follow‐up; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IQR, interquartile range; MSM, men who have sex with men; PWIDs, people who inject drugs; RNA, ribonucleic acid.
a
Applied upper limit of normal (ULN) for AST and ALT: 35 IU/L (females) and 50 IU/L (males).